Suppr超能文献

磁共振成像在评估接受新辅助化疗的乳腺癌患者残留疾病和病理完全缓解中的作用:系统评价。

The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review.

机构信息

Department of Radiology, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands,

出版信息

Insights Imaging. 2013 Apr;4(2):163-75. doi: 10.1007/s13244-013-0219-y. Epub 2013 Jan 29.

Abstract

OBJECTIVES

This systematic review aimed to assess the role of magnetic resonance imaging (MRI) in evaluating residual disease extent and the ability to detect pathologic complete response (pCR) after neoadjuvant chemotherapy for invasive breast cancer.

METHODS

PubMed, the Cochrane Library, MEDLINE, and Embase databases were searched for relevant studies published until 1 July 2012. After primary selection, two reviewers independently assessed the content of each eligible study using a standardised extraction form and pre-defined inclusion and exclusion criteria.

RESULTS

A total of 35 eligible studies were selected. Correlation coefficients of residual tumour size assessed by MRI and pathology were good, with a median value of 0.698. Reported sensitivity, specificity, positive predictive value and negative predictive value for predicting pCR with MRI ranged from 25 to 100 %, 50-97 %, 47-73 % and 71-100 %, respectively. Both overestimation and underestimation were observed. MRI proved more accurate in determining residual disease than physical examination, mammography and ultrasound. Diagnostic accuracy of MRI after neoadjuvant chemotherapy could be influenced by treatment regimen and breast cancer subtype.

CONCLUSIONS

Breast MRI accuracy for assessing residual disease after neoadjuvant chemotherapy is good and surpasses other diagnostic means. However, both overestimation and underestimation of residual disease extent could be observed.

MAIN MESSAGES

• Breast MRI accuracy for assessing residual disease is good and surpasses other diagnostic means. • Correlation coefficients of residual tumour size assessed by MRI and pathology were considered good. • However, both overestimation and underestimation of residual disease were observed. • Diagnostic accuracy of MRI seems to be affected by treatment regimen and breast cancer subtype.

摘要

目的

本系统评价旨在评估磁共振成像(MRI)在评估新辅助化疗后浸润性乳腺癌残留疾病范围和检测病理完全缓解(pCR)能力中的作用。

方法

检索截至 2012 年 7 月 1 日的 PubMed、Cochrane 图书馆、MEDLINE 和 Embase 数据库,寻找相关研究。经过初步筛选,两名审查员使用标准化提取表格和预定义的纳入和排除标准,独立评估每项合格研究的内容。

结果

共选择了 35 项合格研究。MRI 评估的残留肿瘤大小与病理学的相关系数良好,中位数为 0.698。报告的 MRI 预测 pCR 的敏感性、特异性、阳性预测值和阴性预测值分别为 25-100%、50-97%、47-73%和 71-100%。MRI 预测 pCR 时存在高估和低估。MRI 在确定残留疾病方面比体格检查、乳房 X 线摄影和超声更准确。新辅助化疗后 MRI 诊断准确性可能受治疗方案和乳腺癌亚型的影响。

结论

MRI 对新辅助化疗后评估残留疾病的准确性较好,超过其他诊断方法。然而,残留疾病范围可能存在高估和低估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d06b/3609956/ba5fee56a124/13244_2013_219_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验